Acino ? Delivering Health

More documents

Recommendations

Info

Development projects Fentanyl (low load) EU & US Characteristics – Monolayer transdermal system for delivery over 3 days – 12 µg/h, 25 µg/h, 50 µg/h, 75 µg/h, 100 µg/h dosage strength – Low drug load of <strong>Acino</strong>’s patch allows to submit in US and EU: > Smaller and less drug load (< 50%) compared to Durogesic ® SMAT > Release of about 90% of total drug (compared to about 40% of reference) – Risk for drug abuse significantly reduced – Lower COGS Status – Pivotal trials planned for May 2013 – Submission in EU June 2014 24
Development projects Goserelin & leuprorelin implants The implant The application system 14 - 22 mm Ø 1.2 – 1.5 mm Medication Subcutaneous injection Active pharmaceutical ingredient (API) in biodegradable matrix Release of API within 1 or 3 months Advantages of <strong>Acino</strong>’s products Covering two different treatment durations Easy-to-handle / easy-to-apply product(s) Small volume of injection (< 0.05 ml) and largely painless application 25
Page 1 and 2: Acino - Delivering Health Investor
Page 3 and 4: Acino - drug delivery specialist, m
Page 5 and 6: Acino’s growth drivers Fully expl
Page 7 and 8: Technology platform Oral modified r
Page 9 and 10: Oral modified release forms MUPS (M
Page 11 and 12: Technology platform Oral dispersibl
Page 13 and 14: Technology platform Transdermal sys
Page 15 and 16: Transdermal systems Why transdermal
Page 17 and 18: Technology platform Extended releas
Page 19 and 20: Extended release parenterals Advant
Page 21 and 22: Development projects Ferrous sulfat
Page 23: Development projects Rivastigmine T
Page 27 and 28: Development projects Goserelin 1 &
Page 29 and 30: Development projects Leuprorelin 1
Page 31 and 32: Acino’s development pipeline Stat
Page 33 and 34: Acino - Delivering Health Thank you
Page 35 and 36: Entering emerging markets / “Swis
Page 37 and 38: Acino Switzerland 2009 BtC markets
Page 43 and 44: Opportunities Products with added v
Page 45 and 46: Acino Switzerland: Product Portfoli
Page 47 and 48: Acino portfolio Roll-out in new ter
Page 49 and 50: Criteria for selecting products for
Page 51 and 52: Acino’s business model (example)
Page 53 and 54: Optimized BtB Concept - Geographica
Page 55 and 56: Technical Marketing and Operations:
Page 57 and 58: Acino’s production importance Tec
Page 59 and 60: Production Technologies: Value for
Page 61 and 62: Pellets Innovative technologies for
Page 63 and 64: Pellet Projects High volume project
Page 65 and 66: Granulates Hot melt granulation Sp
Page 67 and 68: Manufacturing Process 67
Page 70 and 71: Implants Implant manufacturing capa
Page 72 and 73: Opportunity: High Quality Service S
Page 74 and 75:
Summary Focus on niche technologies
Page 76 and 77:
Competitive advantage factor: HighT
Page 78 and 79:
Micro Error Tracking System (METS)
Page 80 and 81:
Strategy to cope with declining mar
Page 82 and 83:
Financials Robert Schmid, Head of I
Page 84 and 85:
Promising potential areas of synerg
Page 86 and 87:
Reduced currency exposure Mepha / C
Page 88 and 89:
Summary and strategy Peter Burema,
Page 90 and 91:
Acino’s growth drivers Fully expl
Page 92 and 93:
Geographic break-down of revenue DE
Page 94:
Acino - Delivering Health Thank you
show all

Acino ? Delivering Health

Create successful ePaper yourself

Delete template?

Save as template?